World Orphan Drug Congress Europe 2025

Topics

• Regulatory challenges surrounding Orphan drug development
• Successful development plan for Orphan Drug
• Commercial aspects of orphan drug development
• Developing patient registries
• Patient perspective

Who should Attend

• CMO, CEO, Corporate Development and CSO from biotechnology companies
• VPs, Presidents, Heads/Managers and Directors of (within sectors – CV, Oncology, AutoImmune and Respiratory): Therapeutic Development, (Orphan) Drug Discovery/Development, Business Unit, Marketing & Medical Affairs, External Affairs, Regulatory Affairs and Market Access From pharmaceutical companies
• Academics, Regulatory Bodies and Research centres